After overlapping the 431 putative targets of atorvastatin with 15 common pathogenic genes between atherosclerosis and NSCLC, then find 4 genes (MMP9, MMP12, CD36, and FABP4) were identified as potential therapeutic targets of atorvastatin for atherosclerosis and NSCLC (Fig. 2C). This evidence concerns the gene CD36 and atherosclerosis.